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Anabolic-androgenic steroids (AAS) are synthetic compounds that are structurally related to
testosterone. AAS are an important class of drugs that are commonly abused in sport and are
classified as prohibited substances according to the World Anti-Doping Agency (WADA).
AAS are metabolized extensively in the human body and excreted to urine mostly as
glucuronides or sulphates. These conjugated compounds are present in human specimens in
low concentrations and for a limited period. Sensitive and specific analytical methods are thus
highly important to be able to detect these compounds for an extended time period in athletes.
These compounds are usually analyzed from biological matrixes after cleavage of the
glucuronide or sulfonate moiety. Direct analysis of intact conjugated steroid metabolites is
an attractive option that involves more straightforward sample preparation. Nonetheless, the
commercial availability of the conjugated reference material is limited.
The first aim of this study was to produce glucuronide-conjugated metabolites of AAS to be
used in the development of methods for doping control. Glucuronide-conjugated metabolites
of anabolic androgenic steroids were produced by in vitro enzyme-assisted synthesis. The
products were characterized by nuclear magnetic resonance (NMR) spectroscopy and mass
spectrometry (MS). The method offers a simple and stereospecific procedure of producing
small amounts of reference material, which are needed in the development and application
of analytical methods for AAS metabolites.
Secondly, these enzymatically synthetized AAS glucuronides were utilized in the
development of a liquid chromatography – mass spectrometry (LC–MS) method for
simultaneous detection of 12 glucuronide-conjugated AAS metabolites in human urine.
Solid-phase extraction (SPE) of AAS glucuronides from urine, as well as LC separation and
mass spectrometric detection, were optimized. The detection was performed by tandem mass
spectrometer (MS/MS) combined via electrospray ionization (ESI). Novel LC–ESI-MS/MS
method was validated, and the robustness and transferability of the developed method was
studied in an interlaboratory comparison among seven laboratories. The recovery, detection
limits, and repeatability of the developed method reached expectations. The interlaboratory
comparison also revealed that the developed method is transferable to other laboratories
equipped with triple quadrupole mass spectrometers. The developed method offers simpler
and a more straightforward as well as sensitive approach to the analysis of exogenous
steroids, without a hydrolysis process and time-consuming sample preparation.
The third part of this study involved gas chromatographic – mass spectrometric (GC–MS)
methods, which with electron ionization (EI) are robust, sensitive, and well suited for
quantitative measurements. High energy incorporated to the analytes, however, results in
fragmentation and often to a loss of sensitivity. Another approach for a more sensitive and
4
specific method for analysis of anabolic steroids from urine, was to combine GC featuring
good resolving power to softer ionization in atmospheric pressure (API). A microchip-based
miniaturized heated nebulizer provides easy interfacing for GCAPI-MS  with  high
ionization efficiency. Two sensitive and selective gas chromatography  microchip
atmospheric pressure photoionization - tandem mass spectrometry (GCμAPPI-MS/MS)
methods were developed, validated and successfully applied to the analysis of anabolic
steroids in authentic excretion urine samples. The anabolic steroids were analyzed from urine
samples without derivatization and as their trimethylsilyl (TMS) derivatives. The feasibility
of GCμAPPI-MS/MS  in  analysis  of  AAS  in  urine  was  studied  and  compared  with
conventional GCEI-MS. Both GCμAPPI-MS/MS methods showed good sensitivity and
quantitative performance, demonstrating their potential to the analysis of biological samples.
The advantage of GC– APPI-MS/MS is to provide soft and efficient ionization that produces
abundant molecular ion or protonated molecule.  The analysis of anabolic steroids without
derivatization resulted in protonated molecules with fragmentation, but TMS derivatives
produced intensive radical cations with only slight fragmentation, ensuring good selectivity
and sensitivity. The TMS derivatives are also more volatile compounds providing better
chromatographic performance. In addition, the fragmentation of the molecular ions of the
TMS  derivatized  steroids  in  μAPPI-MS/MS  is  similar  to  EI,  which  allows  for  the  use  EI
spectral libraries to support with the identification of TMS derivatized steroids. These
methods offer valuable tools for anti-doping laboratories where new analytical strategies are
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1 REVIEW OF THE LITERATURE
1.1 Anabolic-androgenic steroids (AAS)
1.1.1 Origin and effects
Cholesterol  is  the  most  prevalent  steroid  in  all  animals  and  is  essential  for  life.  It  is  the
precursor  to  all  steroid  hormones  (Figure  1).  In  mammals,  steroids  are  divided  into  six
groups based on their individual structure and biology. Androgens, the male hormones, are
one group of steroid hormones, of which testosterone is predominant in humans.
Testosterone (Figure 2) is excreted mainly by testis in males, and by ovaries and placenta
in females [1]. Average plasma levels of testosterone are 0.6 ng/ml in post pubertal males
and 0.03 ng/ml in females. Testosterone and its active metabolites, e.g. dihydrotestosterone
(DHT), are responsible for many changes that occur in puberty (growth, changes in skin,
lowered voice) and they play an important role in stimulating and maintaining sexual
function in man, increase lean body mass, stimulate body hair growth, and sebum secretion.
The metabolic effects of androgens include reduction of hormone binding and other carrier
proteins. Renal erythropoietin secretion is stimulated, and high-density lipoprotein levels
are decreased [2]. Actions of testosterone are divided into two types: anabolic (promotion
of muscular growth) or androgenic (development and maintenance of secondary male
sexual characteristics). Anabolic-androgenic steroids are synthetic derivatives of
testosterone. More than 600 testosterone derivatives have been synthesized in order to
enhance the anabolic effect relative to the androgenic effect [3].
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Figure 1. Biosynthesis of testosterone [1]. Reprinted with the permission of Elsevier.
Figure 2. Significant sites of testosterone for the expression of androgenic and anabolic activities [4].
Reprinted with the permission of Elsevier.
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1.1.2 Clinical use and abuse in sports
AAS are beneficial in therapeutic doses in treatments of several diseases and disorders.
Hypogonadal or ageing men can be treated with androgen replacement therapy [5,6].
Androgen therapy offers support in the treatment of patients experiencing decreased
testosterone plasma levels in HIV [7,8], chronic obstructive pulmonary disease [9], burns
[10,11], renal failure, cancer, liver failure, and postoperative recovery. Anabolic steroids
have the ability to stimulate erythropoiesis and can thus be used for treatment of anemic
patients [12]. Androgens alone or together with estrogens have been used in the treatment
of osteoporosis [13]. According to a report by Tomoda et al. [14], short-term administration
of oxymetholone may have a beneficial effect on damaged myocardium in heart failure.
AAS are also misused in supratherapeutic doses to improve performance in sports and are
classified as prohibited substances according to WADA [15]. The main desired effects of
these testosterone-derived compounds are their potential ability to improve the physical
performance of skeletal muscle and to balance catabolic conditions in the body after stress
[3,16]. In addition, supratherapeutic doses of AAS increase muscle size [17-20]. These are
desired effects also for non-athletes; recreational AAS abuse among adolescents has been
increasing rapidly over the past years [21,22]. In addition to the desired effects on
performance, androgens can also increase aggression and motivation for competition
[23,24]. However, mediated mainly by their androgenic activity, the AAS have the potency
also to cause serious health problems as side effects e.g. cardiovascular or liver diseases
[16].
1.1.3 Structure and nomenclature
The molecular skeleton of androgens is formed by three six-member and one five-member
carbon rings, which are labelled A-D (Figure 2). Usually there is at least one methyl group
(-CH3) at angular positions and many steroids also possess one or more double bonds. Most
steroids have an oxygen atom at C-3. The tetracyclic structure of androgens has up to six
chiral centers (C-5, -8, -9, -10, -13, and -14) allowing 26 isomers. Additional chiral centers
occur if substituents are present (usually in C-17), but possible double bonds reduce the
number of stereoisomers. The configuration in the chiral centers has to be stated in order to
distinguish the three-dimensional shape of the molecule. The A/B ring junction can have a
cis or trans configuration and it has to be specified if the C-5 is saturated. The 5-orientation
gives the molecule a planar shape, whereas the 5-configuration causes a sharp bend in the
structure resulting in different chromatographic, spectroscopic and chemical properties. The
B/C ring junction has the 8/9-configuration (trans) in all common steroids and requires
no illustration. Similarly, the C/D ring junction has trans configuration (13/14) in most
of the steroids. Angular methyl groups in C-18 and C-19 have -configuration [25].
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Functional groups or conjugation in steroid structure, together with the shape of the
molecule, determine the chemical and physical properties as well as interactions with
hormone receptors (androgen receptor) or metabolizing enzymes. Modifications to structure
intend to increase activity, sustain release into the circulation, or to permit oral delivery by
reducing first-pass metabolism in the liver. An example of the latter is alkylation at the C17
position (Figure 2). On the other hand, modifications can increase the toxicity, for example
17-alkylated orally active steroids are hepatotoxic [26]. Structure-activity relationship is
determined by the binding affinity of steroid to the androgen receptor (AR). The 5-
configuration, for example, favors binding to AR making it more active compared to 5
structure [27].  The oxygen atom at C-3 can be in form of 3- or 3-hydroxyl group or as
carbonyl (3-keto-group), which binds more strongly to AR than 3-hydroxy and makes 3-
keto structures generally more active than compounds with the 3-hydroxy moiety. C-17 is
also a common site for substituents. Estrogens and various androgens have a 17-oxo
structure. Estradiol and testosterone possess 17-hydroxy and some pregnanes have 17-
hydroxy groups: 17-hydroxy favors binding to AR and makes compounds with such a
structure highly more active. Any modification or elimination to 17-hydroxy reduces the
activity [25], whereas the presence of a 4-ene-one structure makes the molecule planar and
highly active.
1.1.4 Human metabolism
Within the human body, the nonpolar AAS are transformed extensively by phase-I and
phase-II metabolic reactions. Enzymatically catalyzed phase-I reactions (oxidation,
reduction, hydroxylation, or epimerization) introduce more functionalities into steroid
structure, which increase the polarity and serve as sites for phase-II reactions. Reduction of
C4-C5 double-bonds to yield 5- and 5-saturated structures, 3-keto or 17-keto reduction,
1,2-hydrogenation, 6-, 12-, or 16-hydroxylations, 6,7-dehydrogenation, and 17-hydroxy
oxidation are the main phase-I metabolic reactions for AAS [28]. Phase-I metabolism of
nandrolone is presented as an example in Figure 3.
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Figure 3. Phase-I metabolism of nandrolone. Reduction in A-ring and 17-keto metabolism in D-ring yielding
5/-isomers, 19-norandrosterone (5-estran-3-ol-17-one), and 19-noretiocholanolone (5-estran-3-ol-
17-one).
Phase-II reactions (glucuronidation, sulfation, methylation, acetylation, and conjugation
with amino acids or glutathione) are conjugation reactions, which typically terminate the
activity of the compound. In general, the conjugates are less toxic, less active, and more
hydrophilic than parent compounds enhancing the excretion to urine. Less than 3% of
androgens are excreted in urine in free form [29]. The most common pathways of AAS
conjugation in human body are glucuronidation and sulfation. Both of these conjugation
reactions are enzymatically controlled. Glucuronidation is catalyzed by uridine
diphosphoglucuronosyltransferases (UGTs) and sulfation by sulfotransferase (SULT)
enzymes. In AAS, the most common cites for conjugation reactions are 3- or 17-hydroxyl
groups. Steroids possessing 3-  or  17-hydroxyl groups are mostly excreted as
glucuronides, whereas steroids with 3-hydroxyl structure favor sulfation [30]. The
spectrum and activity of phase-I and phase-II enzymes can differ dramatically both between
individuals as well as within an individual over time. Both external (smoking, medication
or nutrition) [31-34] and internal (age, gender, diseases and genetics) [31,35,36] factors may
have an influence on phase-II enzyme activity. These differences in steroid metabolism







1.1.5 Anabolic steroid glucuronides
Glucuronidation, a major conjugation reaction for steroids, is a bimolecular nucleophilic
substitution (SN2) reaction. Several different functional groups can react with glucuronic
acid to form O-, S-, N-, and C-glucuronides, which means that a wide variety of compounds
are metabolized by glucuronidation [37]. UGTs, membrane-bound conjugating enzymes,
catalyze the reaction where uridine-5’-diphosphoglucuronic acid (UDPGA) acts as a co-
substrate. The polar glucuronide moiety is attached to the steroid structure with reversion
of the configuration yielding a -glycosidic bond. UGTs can be found in several tissues (e.g.
liver, kidney, intestine, lung, and prostate), but the liver is considered to be the major site of
glucuronidation [38-40]. According to recent knowledge, the UGT family contains 117
individual  UGTs  [41]  and  at  least  25  are  found  in  human  [42].  UGT  isoenzymes  are
categorized into four families—UGT1, UGT2, UGT3, and UGT8—on the basis of protein
sequence similarity [40,42]. The enzyme families are further divided into subfamilies
according to the sequence homology [43,44]. The most important enzymes involved in human
steroid glucuronidation belong to the subfamilies UGT1A and UGT2B, but several
isoenzymes belonging to UGT1 and UGT2 families are reported to catalyze steroid
glucuronidation [39]. UGT2B family members 2B4, 2B7, 2B15, and 2B17 play an
important role in androgen metabolism [45,46]. Glucuronide conjugation of a single steroid
is often catalyzed by multiple UGT isoenzymes, due to their broad substrate specificity [47].
To overcome the risks and limitations of sample preparation, analysis methods targeting
intact glucuronide-conjugated steroids are valuable for the pharmaceutical industry, as well
as doping-control, clinical, and forensic laboratories. In such a case, steroid glucuronides
are needed as reference material for method development and identification purposes. In
vivo production of human AAS glucuronides often meets with both ethical and practical
problems, due to the required isolation of pure metabolites from urine and inter-individual
variation in metabolism. Chemical in vitro synthesis methods are most commonly applied
for production of phase-I [48-50] and phase-II [50-55] metabolites of AAS. Some issues
related to chemical synthesis, e.g. formation of racemic reaction mixtures and production of
ortho ester or acyl transfer side-products [56,57], have been reported earlier. An alternative
approach to chemical in vitro glucuronide synthesis is enzyme-assisted synthesis catalyzed
with microsomal UGT enzymes (Figure 4). Enzyme-assisted synthesis allows production of
stereo-specifically pure conjugates which can be considered as the main advantage over the
chemical synthesis. Another advantage compared to chemical synthesis is the simplicity of
the enzyme-assisted synthesis. Chemical synthesis is relatively laborious with several steps,
but enzyme-assisted synthesis can be performed in one volume without protecting or
deprotecting steps. Owing to the stereospecificity and simplicity, enzyme assisted synthesis
offers a practical way to produce small amounts (milligrams) of glucuronides to be used,
for example, in the development of an analytical method. Rat liver preparations as a source
of conjugating enzymes have been used for glucuronidation of e.g., p-nitrophenol [58],
nitrogen containing antidepressants [59], catechols [60,61] nitrocatechols [62,63],
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androsterone, androstanediol, dihydrotestosterone [64], epitestosterone [65], testosterone
[66,67], methyltestosterone [67], nandrolone [67], and neurosteroids [68]. Porcine and
bovine microsomes have also been used as a source of conjugating enzymes [68].
Subcellular fractions, such as pooled human liver microsomes [69] or whole cell systems,
i.e. human hepatocytes [70] and liver slices [71], have also been used as enzyme sources.
Another enzymatic method, where E. coli -glucuronidase is used as a source of
glucuronylsynthase, has been reported [72,73] and utilized to produce a library of steroid
glucuronides [74]. E. coli -glucuronidase is usually applied to catalyze the deconjugation
of glucuronide metabolites [75], where, conversely, the hydrolytic pathway is disabled by
mutation and the resulting glucuronylsynthase enzyme can catalyze the formation of
glucuronide product. Alternative assays have been used for glucuronide syntheses as well,
e.g. fungus Cunninghamella elegans [76], recombinant human enzymes [47,69,77,78], and
in vivo chimeric mouse model, a hybrid capable of producing human metabolites [79].
Figure 4. Formation of 5-MTG in glucuronidation reaction.
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1.2 Analysis of AAS
The World Anti-Doping Code specifies anabolic androgenic steroids as substances
prohibited at all times, i.e. in and out of competition [15]. The testing methods for AAS in
doping contexts begin with initial testing methods (screening analysis) to reveal suspicious
samples, which are forwarded to confirmation procedures. Fast and robust methods are
mandatory in screening assays while specificity is prioritized in confirmation analysis to
achieve indisputable identification of the target compounds. One crucial parameter to
consider is the time period (window of opportunity) in which these compounds can be
detected in the athletes’ samples. Exogenously administered AAS are present in human
specimens, often in low concentration and within a limited time period. Sensitive detection
and selection of a representative sample matrix are thus highly important in all anti-doping
analyses, as well as in the experiments studying the new long-term metabolites for the
extension of detection time.
1.2.1 Requirements
The majority of the anabolic steroids in the WADA prohibited list are of exogenous origin
and, as such, analyzed only qualitatively. WADA has established sensitivity requirements
for these qualitative methods. The minimum required performance levels (MRPL) for the
exogenous non-threshold AAS are 2 ng/ml for dehydrochlormethyltestosterone,
methandienone, methyltestosterone, and stanozolol, and 5 ng/ml for other exogenous non-
threshold AAS in urine samples [80]. The laboratories have the flexibility to select the
method for non-threshold compounds as long as it meets sensitivity requirements (limit of
detection  (LOD) at  least  50% from the  MRPL).  Commonly  used  analytical  methods  are
based on the detection of hydrolyzed phase-II metabolites with LCMS or GCMS after
derivatization [81].
Doping analysis of anabolic steroids that are naturally present in the human body
(endogenous anabolic steroids) requires diverse methods that are based on individual steroid
profiling. The misuse of endogenous AAS (EAAS) is tracked with the steroidal module of
the athlete biological passport (ABP) and “steroid profile” [82]. The ABP is a valuable tool
that was recently implemented in anti-doping work [83,84]. It is based on the individual and
longitudinal monitoring of hematological markers and was recently completed with the
steroid profile module. Steroid profiles include concentration levels of endogenous steroids
in urine and their respective ratios measured from urine samples [85]. Administration of
anabolic steroids may significantly alter these normally robust ratios. The “steroid profile”
is composed of markers (androsterone, etiocholanolone, 5-androstane-3,17 -diol, 5 -
androstane-3,17 -diol, testosterone, and epitestosterone) and their selected ratios. EAAS
concentrations and their ratios may be altered following the administration of synthetic
forms of endogenous AAS, such as testosterone precursors. The two-step procedure of
EAAS testing begins with a screening procedure, the measurement of a “steroid profile” in
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GCMS or GCMS/MS. In case of atypical findings, quantitative analysis is repeated for
confirmation, together with an analysis based on gas chromatographycombustion-isotope
ratio mass spectrometry (GCC-IRMS) of the relevant markers. The latter is needed for the
assessment of endogenous/exogenous origins of testosterone metabolites.
1.2.2 Sample matrixes
The sample matrixes currently used in routine doping control analysis are urine, serum, and
whole blood; however, plasma [86], oral fluid [87], sweat [88] and dried blood spots [89]
are proposed to offer additional information [90]. Urine is currently the most commonly
used matrix in AAS analysis,  as sufficient sample volume is easily obtained. In addition,
concentrations of AAS metabolites in urine are relatively high for an extended period
compared to blood [91,92]. Urine is a complex matrix containing thousands of different
compounds and the steroids of interest are usually present at fairly low concentrations.
Sample pre-treatment is needed in order to reduce matrix effects and to concentrate the
sample, i.e. to improve the selectivity and sensitivity of the analysis.
1.2.3 Sample preparation
Sample preparation is necessary when analyzing anabolic steroids from urine samples due
to the complexity of the matrix. The main goals of sample preparation are to remove
interfering matrix elements and pre-concentrate the sample, in order to increase selectivity
and sensitivity of the analysis. The commonly used sample preparation methods in doping
analysis include liquid–liquid extraction (LLE), solid-phase extraction (SPE), and “dilute-
and-shoot” methods. The applicability of different techniques for extraction of AAS from
urine has been compared [93-95] in a doping analytical context.
Even though the majority of the AAS are excreted to urine as conjugates, they are frequently
analyzed as their hydrolyzed counterparts rather than as intact conjugates. The direct
analysis of AAS conjugates is possible by LCMS [55,96,97], but these non-volatile and
thermally unstable conjugates are not typically amenable to GCMS. Therefore, the
glucuronide-conjugated AAS are hydrolyzed enzymatically with -glucuronidase from
digestive juice of Helix pomatia (H. pomatia)  or from Escherichia coli (E. coli) prior to
GCMS analysis [98]. Sulphate-conjugated AAS are not routinely included in human anti-
doping screens, but they can be hydrolyzed with arylsulfatase [99] or via solvolysis
[100,101]. The cleavage of both glucuronide and sulphate conjugates can be performed
using H. pomatia which contains both -glucuronidase and arylsulfatase activity [102].
However, problems associated with the production of artefacts [103], conversion between
steroids [104] and incomplete hydrolysis [105,106] have been described when using H.
pomatia in hydrolysis of AAS. Additionally, detection can be hindered by interfering peaks
or elevated background noise [107]. The WADA technical document states that E. coli
should be used as a source of -glucuronidase in order to prevent these problems associated
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with H. Pomatia, and to guarantee a harmonized approach within the anti-doping
laboratories to ABP steroid profiling [82].
For LCMS-screening, sample preparation can be as simple as a dilution with an
appropriate solvent in order to reduce the matrix effect [108]. The dilution can be as minimal
as a 10% addition of acetonitrile (ACN) [109], but the factor is usually higher being 1:1
[110-112] or 1:10 [113,114], or even 1:25 [108,115]. Dilute-and-shoot sample preparation
methods are fast and cheap, but they have some drawbacks, such as increased limits of
detection [97], higher matrix effects [97], and variation in retention times [108]. Dilute-and-
shoot methods are suited to easily ionized compounds with higher detection limit
requirements [108]. Usually more efficient and selective cleaning procedures are necessary
to achieve lower detection limits.
Traditionally, LLE has been widely used for the analysis of AAS in urine, with different
extraction solvents for example tert-butyl methyl ether [116-119], diethyl ether [81,120],
ethyl acetate [121], or n-pentane [116]. Shortly after the introduction of the first prepacked
and disposable SPE cartridge in the late 1970s, it was used for urinary steroid extraction
[122] and nowadays it has become the method of choice for AAS extraction. A wide variety
of  different  types  of  SPE  cartridges  have  been  used,  for  example  XAD-2  [49]  or  C18
[119,123,124], alone or in combination with two different cartridges [125,126]. The
performance of different SPE cartridges has been compared in the analysis of non-
conjugated AAS [93,127-129]. Oasis HLB seems to be an efficient sorbent and in
combination with LLE with methyl tert-butyl ether (MTBE) it has provided high recoveries
and selectivity especially towards more polar steroids [93]. The Oasis HLB cartridge
contains both hydrophilic and lipophilic groups and thus allows good recoveries for many
anabolic steroids [130]. In an animal-sample context, five SPE cartridges were compared
for extraction of steroid glucuronides and sulphates from urine samples [128]. A strong
anion exchanger on a functionalized silica (SAX) cartridge gave the best purification for a
large number of glucuronides and sulphates. In a study by Pu et al. [129], several different
SPE cartridges were compared for AAS glucuronides in a complex matrix of equine urine.
According to their results, Certify II with mixed mode sorbent combining non-polar C8 and
strong anion exchange (SAX) functionalities resulted in the best recoveries for AAS
glucuronides.
Alternatively, microtechniques such as solid phase microextraction (SPME) [131-133],
liquid-phase microextraction (LPME) [94,134] or microextraction by packed sorbent
(MEPS) [133] might be applied to minimize the sample throughput time or solvent amounts
used. Other approaches to clean-up the urine samples have also been reported, such as
highly selective immunoaffinity chromatography [135] and lately online turbulent flow
chromatography (TFC) [136] and two-dimensional (2D) online trapping [137]. The TFC
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and 2D online trapping enables direct injection of native urine samples providing clean-up
and pre-concentration.
1.2.4 Analytical methods
Radioimmunoassays (RIA) were among the early methods used to analyze AAS and are
still widely used in clinical laboratories owing to their ease of use, rapid throughput, and
sensitivity [138,139]. Other detection methods such as direct immunoassay (IA) [140] or
enzyme-linked immunosorbent assay (ELISA) [141] have also been used, but they have
limitations such as non-specificity [142,143]. The mass spectrometric detection of AAS
metabolites has replaced almost all other methods in anti-doping laboratories due to its
selectivity and sensitivity [144]. It can be used in combination with gas or liquid
chromatography to simultaneously separate and determinate multi component steroid
mixtures. Owing to the simplicity and sensitivity accomplished by LCMS methods, they
are increasingly used in AAS analysis. Despite the continuing advance of LCMS in AAS
analysis, the necessity for GCMS remains undeniable.
1.2.4.1 GCMS
GCMS with electron ionization has traditionally been the method of choice for AAS
analysis in anti-doping routine. The method provides excellent chromatographic resolution,
high sensitivity, and good quantitative performance. However, AAS are most often
derivatized for GCMS analysis in order to improve their volatility and thus the
chromatographic performance. Trimethylsilylation using N-methyl-N(trimethylsilyl)
tri uoroacetamide (MSTFA) [49,98,145,146] as a reagent is the most commonly used
derivatization method with AAS. Tert-butylsilyl derivatives could be used in order to
achieve higher mass increase, more intensive molecular ion and diagnostic ions above m/z
300  with  EI  [116,147].  Other  derivatives  used  are,  for  example,  acyl  derivatives  with
steroids containing nitrogen, such as stanozolol or stable tri-, penta- or heptafluoro amines
produced in conjunction with silylation of hydroxyl groups [148]. One disadvantage of the
GCEI-MS is that the derivatized AAS are strongly fragmented in EI process, which results
in decreased sensitivity and/or specificity in selected ion monitoring or in selected reaction
monitoring, since ion current is divided over several fragment ions and the structure-
specificity of the fragments may be compromised as well. Chemical ionization (CI) provides
an ionization method softer than EI. An intense protonated molecule with less fragmentation
is typically observed in the analysis of AAS with CI [149].
Classical CI by using methane, isobutene, or ammonia as reagent gases has been commonly
applied to the analysis of labile compounds in GCMS. In this method, the ionization occurs
in a vacuum. Atmospheric pressure chemical ionization (APCI) methods have been
increasingly used in GCMS (Table 1). Dzinic et al. [150] presented the interfacing of GC
to MS by using APCI for the first time about four decades ago. Ten years later Revelsky et
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al. [151,152] presented APPI interface for GCMS. Although the potential of GC coupled
with atmospheric pressure ionization to MS (GCAPI-MS) has been demonstrated during
the last decades, the technique has not made a breakthrough to routine analyses. There are
now commercial interfaces for GCAPI-MS with APCI and APPI, although several other
techniques such as ESI [153], low temperature plasma (LTP) [154] and atmospheric
pressure laser ionization (APLI) [155,156] have also been presented during the last years
[157]. Recently, novel high sensitivity capillary APPI (cAPPI) interfaces have been
introduced for GCMS [158,159]. The cAPPI utilizes an extended heated transfer capillary
(between the atmosphere and the vacuum of the MS) with an MgF2 window, through which
vacuum UV light (10 eV) from an external source enters the capillary. Since the sample is
introduced, vaporized, and photoionized inside the extended capillary, ion transmission into
MS is maximized resulting in excellent overall sensitivity. In the recent study by Haapala
et  al.  [158],  the  feasibility  of  the  GCcAPPI-MS  method  was  tested  in  the  analysis  of
steroids in artificial urine. The method showed good quantitative performance and limits of
detection down to pg/ml range.
Moreover, there is growing interest in the miniaturization of analytical devices by using
microchip technology. The advantages of miniaturization include higher sensitivity, faster
analysis, reduced sample and solvent consumption, and lower manufacturing cost. For these
reasons, a miniaturized heated nebulizer [160] was developed for microchip-based APPI
[161] and APCI [162] for LCMS and GCMS analysis. The performance of the heated
nebulizer microchip as a GCMS interface has been demonstrated in APPI and APCI
modes, for example in the analysis of volatile organic compounds [162], drugs [163,164]
polyaromatic hydrocarbons [163], and polychlorinated biphenyls [165].
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Table 1. GCAPI-MS
Analytes Matrix Ionization Analyzer Type Pub. year Ref.
VOCs and testosterone - μAPCI QQQ S 2006 162
APPI qTOF S 2007 166
PAHs - μAPPI QQQ S 2007 163
PAHs - APCIAPLI TOF S 2008 167
PCBs soil μAPPIμAPCI ion trap S 2008 165
VOCs - ESIAPCI QQQ S 2008 153
SARMs urine μAPCI Orbitrap S 2010 164
impurities pharmaceuticals APCI TOF C 2010 168
metabolic fingerprinting bacterial culture APCI-I TOF C 2011 169
phenolic compounds olive oil APCI TOF C 2011 170
acrylic adhesives food packing APCI QTOF C 2012 171
PAHs and phthalates - APPI QQQ S 2012 172
volatile compounds perfume APPI (toluene) LIT-orbitrap S 2012 173
VOCs - LTP qTOF S 2013 154
metabolic profile




and car interiors APCI TOF C 2013 175
neurosteroids urine APPI S 2013 176
steroids urine cAPPI ion trap S 2013 158
methyl phosphonic acid
esters - APPI QQQ 2014 177
fatty acids bacterial culture APCI-II TOF C 2015 178
food contaminants food packing APCI QTOF C 2015 179
environmental pollutants - DA-APPI (toluene)and APLI Orbitrap S 2015 156
anabolic steroids urine APCI QQQ C 2017 180
anabolic steroids urine ESI LTG orbitrapand QQQ S 2017 181
LTP -low temperature plasma; VOC-volatile organic compound; S-self-made C-commercial; DA-dopant-assisted
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1.2.4.2 LCMS
Liquid chromatography connected to mass spectrometry (LCMS)  has  become  a  more
important technique over the last decade and is nowadays widely used with GCMS to
cover the wide range of target compounds in anti-doping analyses [90]. The advantage of
LCMS is that AAS can be analyzed without the time-consuming derivatization step that is
necessary in GCMS. The majority of the published LCMS methods for AAS are focused
on hydrolyzed steroids from glucuronide-conjugated fractions [107,120,182,183], although
LCMS could allow for direct analysis of intact conjugated steroid metabolites without
time-consuming hydrolysis (Table 2).
The chromatographic separation of AAS is of great importance as many isobaric AAS
cannot be separated by MS alone. A wide variety of different reversed phase columns have
been used in AAS analysis (e.g. C18, C8, phenyl, and cyano) and their applicability has
been compared [130]. Nowadays, ultra-high performance liquid chromatography (UHPLC)
has become the technique of choice for steroid analysis as it provides improved resolution
resulting in faster analysis, as well as improved specificity and sensitivity compared to high
performance LC.
Electrospray ionization (ESI) [55,107,184], atmospheric pressure chemical ionization
(APCI) [185-188], and atmospheric pressure photoionization (APPI) [189-193] have all
been used in LC–MS analysis of AAS in biological samples in a human and animal testing
context. LCESI-MS  was  applied  for  the  first  time  in  the  analysis  of  steroids  and  their
conjugates in 1992 [194] and after that ESI has been the most widely used ionization
technique in the analysis of AAS by LCMS (Table 2). ESI provides very soft and efficient
ionization method for medium polar, polar and ionic compounds producing typically
abundant protonated or deprotonated molecules or adduct ions (e.g. [M+NH4]+ or [M+Na]+)
with minimal fragmentation. ESI, as a soft ionization method, is especially suitable for labile
compounds such as AAS conjugates, which are dissociated when more energetic ionization
methods such as APCI and APPI are used. However, the ionization efficiency for neutral or
non-polar compounds, such as AAS without a keto function at position 3 or conjugated
double bond (4-ene-3-one), is limited with ESI [107]. Moreover, ESI is prone to matrix
effects, which may have a significant contribution to the quality of the analysis [195]. For
these reasons APCI and APPI have been used as alternative ionization methods in the
analysis of AAS by LCMS.
APCI and APPI provide high ionization efficiency for both non-polar and polar compounds
and are thus well applicable to the analysis of non-conjugated AAS [185,186,188,196]. In
APCI and APPI, the sample solution is vaporized by a heated nebulizer, forming gas-phase
molecules  of  the  analyte  and  solvent.  Ionization,  in  the  gas  phase  via  proton  transfer  or
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charge exchange reaction, is initiated by a corona discharge needle (APCI) [150] or by
vacuum ultraviolet lamp emitting 10 eV photons (APPI) [197,198]. APCI and APPI provide
improved ionization efficiency for less polar AAS, they are less susceptible to ion
suppression and tolerate higher salt  buffer concentrations than ESI.  As a disadvantage in
steroid analytics, the higher energy associated with APCI and APPI usually results in
fragmentation of conjugated AAS hindering their direct analysis, especially regarding the
information on intact structure and molecular weight.  Methods have been published for
steroid analysis by APPI with different dopants for example with toluene [189,191-193],
acetone [189,191], chlorobenzene [176], anisole [191], THF [191], and also without dopant
[199]. A profound review of APPI mass spectrometry and combinations with different
separation techniques have been published recently [200].
For mass spectrometric measurements, the preferred analyzer type depends strongly on the
purpose of the application and can be performed with several different types of analyzers.
Generally, low-resolution instruments (e.g. triple quadrupole) are preferred for quantitative
analysis, while high-resolution instruments are selected for untargeted approaches,
identification, or for the analysis of large molecules. In AAS analyses, triple quadrupoles
are versatile and commonly used as they offer good selectivity, sensitivity, quantitative
performance, and several scan modes (SRM, full scan, product or precursor ion scan, and
neutral loss scan). Selected-reaction monitoring (SRM) mode with triple quadrupole is the
method-of-choice in routine and high-throughput AAS analysis owing to the high sensitivity
and robust quantitative performance (Table 2). Despite structural modifications, the core
structure of AAS often remains the same and produces general fragments which could be
targeted as group-specific ions.
Similar to the drugs-of-abuse domain, the recent years have demonstrated so called
“designer steroids” as a threat to anti-doping analyses [48,201]. Untargeted profiling has
been found to be an efficient screening tool, offering complementary information to
common testing methods. Precursor ion scanning offers a general screening method for
anabolic steroids with common fragments [107,183,202]. With untargeted methods, and
efficient data processing systems it is possible to monitor a large number of analytes in a
single  experiment  with  high  sensitivity  and  specificity  [203].  In  addition  to  modern
analytical equipment, comprehensive knowledge of the metabolism as well as mass
spectrometric behavior of AAS are also key elements when establishing new methods.
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Table 2. Examples of published LCMS/MS methods for the analysis of intact AAS conjugates. S=sulphates,
G=glucuronides, ref.=reference
Analytes Matrix Preparation Separation Ionization Detection LODng/ml Ref.
S -  - HPLC (C18) ESI+ QQQ 55
G, S urine SPE HPLC (C18) ESI+ QQQ - 124
G, S urine SPE (C18 bond eluteLRC) HPLC (C18) ESI+ QQQ ~3 195
204
G, S urine SPE (Strata X) HPLC (C18) ESI- QQQ 0.8-1 205




LLE (DEE, ethyl acetate)
HPLC (C18) ESI+ QQQ 2-15 94
G, S urine SPE (C18 and NH4+) HPLC (octadecyl) ESI- QQQ - 206
mesterolone S, G urine LLE (MTBE and ethylacetate) and direct inj. HPLC (C18) ESI+/- qTOF - 207
urine SPE (Oasis HLB) UHPLC (C18) qTOF 130
G, S urine SPE (C18+DEA) (S)SPE (Certify II) (G) HPLC (C18)
ESI – (S)
ESI+ (G) Ion trap - 129
S urine SPE (OasisWAX) HPLC (C18) ESI- Ion trap 1 (LOQ) 208
G urine SPE C18 UHPLC ESI- QQQ 54
G, S urine LLE (ethyl acetate)SPE (SAX)
UHPSFC
BEH, BEH 2-EP ESI- QQQ 0.1-0.5 209
G, S urine LLE (ethyl acetate)SPE (SAX) UHPLC (C18) ESI- QQQ - 128
G urine SPE (Oasis MCX) HPLC (C18) ESI+/- QQQ 0.1 210
methenolone S urine LLE (ethyl acetate) HPLC (C18) ESI+/- qTOF - 211
androsterone G urine No sample preparation No chromatogr. DESI QQQ 10 212
methandienone G urine LLE (MTBE) and SPE(C18) UHPLC (C18) ESI+/- QQQ - 213
stanozolol S urine SPE (C18) UHPLC (C18) ESI+/- QQQ - 214
4-chloro-
metandienone S urine LLE (ethyl acetate) UHPLC (C18) ESI- QQQ - 215
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2 AIMS OF THE STUDY
The overall aim of this research was to develop sensitive and specific mass spectrometric
methods for the analysis of anabolic steroids in order to extend the detection time of target
compounds in human urine samples collected for anti-doping purposes.
The more detailed aims of the studies were:
 Optimization of a rapid production pathway of stereochemically pure AAS
glucuronides which are needed in the development of analytical methods in forensic
or pharmaceutical sciences, as well as in doping control. (I)
 Production of steroid glucuronides via an enzyme-assisted synthesis route in order
to fulfil the significant drawback of the conjugate analysis and to overcome the lack
of reference material. (I)
 To achieve higher sensitivity and specificity by direct analysis of steroid metabolites
in urine samples with a simplified sample preparation procedure and LCMS-based
method which can be transferred to a routine anti-doping laboratory. (II)
 To combine gas chromatography with an atmospheric pressure mass spectrometer
using microchip technology and to demonstrate the performance of microchip APPI
in the analysis of anabolic steroids in biological matrixes. (III, IV)
29
3 MATERIALS AND METHODS
3.1 Reagents and solvents
All solvents were of HPLC grade and all other reagents were of analytical grade. Liver
microsomes were prepared from Aroclor 1254 induced (a single dose of 500 mg/4.5 mL
olive oil/body weight) male Wistar rats (n = 5) at the department of Industrial Hygiene and
Toxicology (Finnish Institute of Occupational Health, Helsinki, Finland) according to
previously described procedure [216]. The treatment of the animals was approved by the
local ethical committee for animal studies. BCA protein assay kit (Pierce, IL, USA) was
used for the determination of protein concentration (18.5 mg/mL), which was used to
standardize the amount of microsomal protein in the synthesis.
3.2 Steroids and steroid glucuronides
The selection of the compounds in this work represent the parent compounds and
metabolites which can be detected in human urine after dosing with anabolic steroids (e.g.
methandienone, methenolone, methyltestosterone, nandrolone, and testosterone), which are
all reported to be misused by sportsmen [217]. The selection also represents compounds
with  small  differences  in  the  substitution  of  carbons  1,  3,  5,  10,  and  17.  Nomenclature,
precursors, and structures of the AAS glucuronides, as well as sources of the steroid
aglycones of this study, are presented in Table 3. AAS glucuronides were prepared via
chemical synthesis at the German Sport University or via enzyme-assisted synthesis at the
University of Helsinki, Finland (Table 3). Nomenclature, structures, and molecular weights
of the studied anabolic androgenic steroids are presented in Table 4. Nandrolone (NAN)
was purchased from Diosynth (Oss, The Netherlands) and all other anabolic steroids were
from the National Measurement Institute (Sydney, Australia).
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Table 3. Nomenclature, precursors, structures, and molecular weights (Mw) of the AAS glucuronides, as well
as sources of the steroid aglycones used as starting material. (DSHS = Institute of Biochemistry, Cologne,
Germany; S = Steraloids, Wilmington, USA)
Abbrev. Compound Precursor Structure Source Mw
5-NG 5-estran-17-one-























































































Table 3. See previous page for the title of the table.
Abbrev. Compound Precursor Structure Source Mw











































































Table 4. Nomenclature, structures, and molecular weights (Mw) of the studied anabolic androgenic steroids.
Abbrev. Trivial name IUPAC name Structure Mw Mwbis-O-TMS
TES Testosterone 17 -Hydroxy-4-androsten-3-one 288 432
NAN Nandrolone 17-Hydroxy-19-nor-4-androsten-3-one 274 418











































3.3 Production and characterization of steroid glucuronides
In this study, enzymatic synthesis method was selected for the preparation of glucuronide-
conjugated AAS-metabolites. Synthesis conditions were optimized in small-scale studies in
a total volume of 100 L with respect to concentration of the substrate 1–1000 M (AAS or
its phase-I metabolite), UDPGA 0.5–10 mM, and enzymatic protein 0.1–1.85 mg/mL.
Optimization of each parameter was carried out in turn while keeping the other parameters
constant in an overnight incubation. The concentrations of constant components were
50 M (substrate), 5 mM (co-substrate), 0.5 mg/mL (protein) and incubation time of 2 h. -
glucuronidase inhibitor, d-saccharic acid 1,4-lactone (5 mM), was added to the reaction
mixture to minimize the risk of hydrolysis by -glucuronidases of the tissue preparation.
Incubation reaction was carried out in 50 mM phosphate buffer (pH 7.4) with 5 mM MgCl2.
After centrifugation, the internal standard (ISTD, d3-5 -MTG) was added to the supernatant
and purified in SPE prior to LC–MS/MS analysis.
For the upscaled synthesis of AAS glucuronides, the steroid aglycone was diluted in 2 mL
of methanol and filled up to the total volume of 20 mL of the earlier-described phosphate
buffer. The reaction was initiated with the addition of UDPGA, carried out in a water bath
of 37 °C for 12–15 h with continuous magnet stirring, and terminated by transferring the
incubation mixture to an ice bath, and precipitating the enzymatic protein with
dichloromethane, which also extracted the excess of starting material. The aqueous phase
of the synthesis, containing the AAS glucuronide, was removed and further purified by
solid-phase extraction (SPE) using a C18 cartridge (Isolute, 100 mg, International Sorbent
Technology, UK) according to the method described earlier by Borts and Bowers [195],
except for an additional SPE step, which was added to the procedure to ensure the purity of
steroid  glucuronide  fraction  with  the  final  elution  of  60%  methanol  in  water.  The  AAS
glucuronide fraction was then evaporated to dryness at 60 °C with nitrogen and
reconstituted in LC eluent.
The synthesized anabolic steroid glucuronides were characterized by MS and NMR. The
instrument used in MS and MS/MS measurements was Applied Biosystems API3000
(Perkin-Elmer SCIEX, Concord, ON, Canada) triple quadrupole instrument with a turbo
ionspray  source.  Both  positive  and  negative  ion  modes  of  ESI  were  used.  The  MS  and
MS/MS spectra were measured by using direct infusion of the purified compounds dissolved
in 7.5 mM ammonium acetate in water–methanol (50–50, v/v). In negative ion mode, the
pH of the solvent was neutral, whereas in positive ion mode the pH was adjusted to 4.2 with
formic acid. The recorded mass range in MS and MS/MS experiment were m/z 100–600 and
m/z 50–550, respectively. The 1H NMR experiments were carried out on a Varian Unity 500
spectrometer at 23 °C using a gHX nano-NMR probe. Acetone-d6 was used as solvent for
MTG, 5 -EPIM, and 5 -EPIMG, whereas all the other compounds were dissolved in
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methanol-d4. The 1H chemical shifts were referenced to residual acetone or methanol, 2.05
and 3.31 ppm, respectively.
3.4 Urine samples and sample preparation
The collected urine samples were stabilized with sodium azide (NaN3)  and  stored  in  a
refrigerator at +5 C (I, II) or frozen (III, IV). Spiked urine samples were prepared by adding
all the glucuronides or steroids as a mixture into a blank urine, which was a pool of six male
and  six  female  urine  samples  stored  frozen  until  use.  Excretion  studies,  approved  by  the
local ethical committee, were performed with nandrolone, methenolone, methyltestosterone
(II), and methandienone (III, IV). In the inter-laboratory comparison (II), each excretion
study sample was provided at approximately 20 ng/mL (“low”) and 200 ng/mL (“high”)
concentration.
The urine samples were prepared with solid phase extraction (SPE) (I, II) or LLE (III, IV).
In  direct  LCMS/MS analysis, the urine sample was buffered and extracted in SPE
procedure with polymeric sorbent cartridge (Waters, Oasis HBL, 30 mg/1 cc). The eluted
methanolic fraction was further evaporated to dryness and the sample was reconstituted to
LC–MS eluent. In the indirect GCμAPPI-MS/MS analysis of AAS the urine sample was
first hydrolyzed and then extracted with n-pentane. The buffered urine sample was
hydrolyzed with -glucuronidase of Helix pomatia, (55 °C for 2 h). After cooling to room
temperature, the pH was adjusted to 9.2 and LLE was performed with n-pentane. The
pentane layer was evaporated to dryness and the dry residue was either diluted to ethyl
acetate (III) or derivatized with MSTFA (IV) prior to GCAPPI-MS/MS analysis.
3.5 LCMS analysis of conjugated steroid glucuronides
The LC set-up consisted of a Hewlett-Packard model 1100 binary pump and autosampler.
An endcapped cyano (CN) column (Phenomenex Luna CN, 150 x 2 mm i.d., particle size
3 m) was used. Eluent A was 5 mM ammonium acetate/acetic acid buffer (pH 3.5) in water
and eluent B was 5 mM ammonium acetate/acetic acid buffer (pH 3.5) in acetonitrile:water
(9:1,  v/v).  LC  flow  rate  was  0.2  mL/min.  The  analytical  run  was  initiated  with  a  1  min
isocratic step of 5.6% B, then increased in linear ramp to 16.6% B in 1 min, and finally to
44.4% in 18 minutes. A 5 min clean-up step (90% B) was utilized prior to a final
equilibration step of 2 min (5.6% B). The injection volume was 10 L. The LC flow rate
(0.2 mL/min) was post-column split 1:10 (Accurate; LC-Packings, The Netherlands) before
introduction to the MS.
The mass spectra were recorded by an Applied Biosystems API3000 (Perkin-Elmer SCIEX,
Concord, ON, Canada) triple quadrupole instrument with a turbo ionspray source. Analyses
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were carried out in positive ion mode ESI. The ionspray voltage and orifice (declustering)
voltage were 5500 V and 20 V, respectively. Purified air (custom-made; Atlas Copco,
Belgium) was used as the nebulizing gas and the curtain gas. Nitrogen (Generator Systems
75-72; Whatman, USA) was applied as the collision gas and turbo gas. The turbo gas flow-
rate was adjusted to 5 L/min at 350 C. In direct injection studies with MS, the solvent flow
rate  was  0.6  mL/h  and  measured  mass  range  was  m/z  100-600,  whereas  in  MS/MS  the
collision gas was nitrogen and collision energy (CE) was optimized with an offset range of
5-70 V (positive ESI) and 5-130 V (negative ESI) within full scan range of m/z 50-550.
3.5.1 Validation and inter-laboratory comparison
Anabolic steroid glucuronides were spiked as a mixture into blank urine, which was a pool
of six male and six female urine samples stored frozen until use. Detection limits (signal-
to-noise ratio (S/N)  3, determined by using standard deviation of the analyte peak height
versus background noise), recovery (n=5), repeatability of injection (n=5), within-day
repeatability (n=5), and between-day repeatability (n=5) were investigated. Linear and
quadratic regression models of concentrations of AAS glucuronides in urine (1-60 ng/mL)
were examined with respect to peak area.
Each laboratory used the distributed reference material for the tuning and adjusting of the
LC and MS instrument parameters for an in-house method and were then requested to
analyze individual and authentic urine samples resulting from excretion studies with
nandrolone (Sample 1), methenolone (Sample 2), and methyltestosterone (Sample 3),
comprising four selected steroid glucuronides as target compounds, namely 5-NG (in
sample  1),  5-MEG  (in  sample  2),  5-MTG,  and  5-MTG  (both  in  sample  3).  Each
excretion study sample was provided at approximately 20 ng/mL (“low”) and 200 ng/mL
(“high”), and the laboratories performed the analysis of both levels as triplicates, together
with three replicates of drug-free urine samples fortified with each steroid glucuronide
reference material (positive control, 0.4 nmol/mL, corresponding to 181-193 ng/mL).
Maximum amount of identification (ID) points (18) was assigned to a specific target analyte
which fulfilled the prevailing WADA-criteria [218] for relative ion ratios for each SRM-
transition (n=3) in every sample replicate (n=3) at both concentration levels (n=2).
Reference material and blank samples were provided by the German Sport University,
distributed together with the authentic urine samples to the participating laboratories by
courier mail, and stored in a refrigerator prior to analysis. Moreover, a recommended sample
preparation protocol, suggested LC conditions, as well as the study protocol, were delivered
to all participants.
Six out of seven participating laboratories utilized triple quadrupole mass spectrometers and
one laboratory employed an ion trap analyzer. For the ionization, six laboratories used ESI
with probe temperatures varying from 240 C to 350 C and one laboratory employed APCI
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with 400 C probe temperature. Either argon or nitrogen was applied as collision gas in
triple quadrupole mass spectrometers and helium as damping gas in ion trap mass
spectrometer. Specific instrumental information and modifications to the suggested protocol
from each laboratory are described in Table 12.
3.6 GCMS analysis of anabolic steroids
GC setup consisted of a Hewlett-Packard 5890 series II gas chromatography equipped with
a CTC-A200S autosampler, a split/splitless injector, and a column transfer line. Helium was
used as a carrier gas. The analytical column was a nonpolar forte BXP 5 from SGE (15 m x
0.25 mm. x 0.25 μm) with a 1.5 m long methyl deactivated fused-silica precolumn. The
analytical column was connected to the transfer capillary of HN microchip with a press fit
junction.	The transfer capillary was threaded through a heated transfer line comprising a
heated MSD transfer line (300C) connected to a self-made transfer line which was heated
(290C) with a resistance wire. The HN microchip was placed in a custom-made clamp
equipped with electrical connections for the heating and with tubing for the auxiliary gas.
The HN microchip (Figure 5) consists of a silicon plate and a Pyrex glass cover and features
a sample introduction channel, an auxiliary gas inlet hole, a vaporizer channel, a thin film
metal heater, and a nozzle. The channels and gas inlet are centrally located and DRIE etched
(deep reactive ion etching) to the silicon wafer. The integrated platinum heater was sputtered
on the Pyrex glass cover, which was then anodically bonded to the silicon wafer. The
deactivated silica capillary (SGE, Victoria, Australia) for sample introduction and connector
for auxiliary gas tubing (Nanoport, Upchurch Scientific Inc., Oak Harbor, WA) were glued
to silicon wafer with high-temperature-resistant epoxy. A detailed description of the
fabrication process has been described previously [160].
Figure 5. (A) Schematic view of the microchip from the heater side. (B) A photograph of a microchip with
Nanoport connector and transfer capillary. Reprinted with the permission of the American Chemical
Society.
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The mass spectra were measured by a PE Sciex API 3000 triple quadrupole mass
spectrometer, but the conventional ion source was replaced with a nanospray stand to enable
positioning of the HN microchip at about 1 cm distance from the MS orifice. Analyses were
carried out in positive ion mode APPI. A vacuum UV krypton dc discharge photoionization
lamp with 10 eV photon energy was used for ionization. A syringe was used to deliver the
dopant (toluene (III) or chlorobenzene (IV), flow rate 3.5 L/min) to the auxiliary gas line.
The repeller voltage and orifice (declustering) voltages were 1300 and 20 V, respectively.
Nitrogen was applied as the auxiliary, curtain, and collision gas. The auxiliary gas flow rate
(80 mL/min) was controlled with a mass flow 	controller. The dopant was delivered coaxially
to the auxiliary gas line with a syringe pump. The microchip was heated with dc power
supply (2,2 W (III) 3,5 W (IV)) and positioned in front of the curtain plate of the MS. More
specific details of the system setup are described in a publication by Haapala et al. in 2007
[163].
In study III, the scan and product ion spectra were measured from m/z 50 to 350 with a speed
of 1 scan/s. In MS/MS, the collision energy was optimized within offset range 5–70 V and
the scan range was set to m/z 50–350. In the final GC–APPI–MS/MS method the collision
energy was 12–38 V, three specific product ions per analyte were monitored in selected
reaction monitoring (SRM) mode, and the measurement was divided into four scanning
segments.  Analyst  1.4.2.  software  (Applied  Biosystems/MSD  SCIEX  Instruments)  was
applied to data processing.
In study IV, the measured mass range was extended to also cover the higher mass TMS-
derivatives, being from m/z 50 to 470. The MS parameters were optimized with repeated
analyte peaks generated by running the GC isothermally and making several split injections
of  standard  solutions.  Two  specific  product  ions  per  analyte  were  monitored  with  a
scheduled SRM algorithm with a 15 s detection window. Analyst 1.5 software was used for
data acquisition and processing.
Repeatability (within-day and injection), linearity, LOD, and limit of quantification (LOQ)
were investigated in the method validation. A drug-free pool of blank urine samples from
five individuals spiked with a mixture of the AAS served as a positive quality control in the
analyses. In the study with underivatized steroids (III), the positive controls were spiked
within the range of 0.1-500 ng/mL, whereas for derivatized steroids (IV) the range of the
positive controls was 0.1–100 ng/mL of each analyte. Methyltestosterone (MTS) was used
as an internal standard and spiked at 25 ng/mL and 10 ng/mL in studies III and IV,
respectively. The method applicability was tested with excretion urine samples obtained
from United Medix Laboratories and the sample preparation was as described above
(section 3.4). Calibration curve (0.5–100 ng/mL), reagent blank, and urine blank samples
were prepared together with the excretion study samples.	
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4 RESULTS AND DISCUSSION
4.1 Production of AAS glucuronides
4.1.1 Enzyme assisted synthesis
Enzyme assisted synthesis method was used to produce small amounts of steroid
glucuronides. Glucuronidation synthesis was optimized using incubation volumes of
100 L with respect to substrate (steroid aglycone), co-substrate (UDPGA), and UGT-
enzymes (microsomal protein) concentration, in order to rationalize the consumption of
expensive starting materials, especially that of UDPGA. The optimization experiments were
carried out with 10% methanol, which was a compromise between dissolution of non-polar
steroids and denaturation of enzyme protein. All the tested steroid substrates were able to
conjugate via enzyme-assisted pathways using rat liver microsomes, and the optimal
conditions for the various substrates were almost the same (Table 5). None of the steroids
showed any substrate inhibition within the concentration range of 1–1000 M, but the
plateau of glucuronidation was observed at 500–1000 M, except for 5 -NG, for which it
was 250 M. The first point of the plateau was selected as the concentration level for the
bulk synthesis. The increase of UDPGA concentration increased the yield of the
glucuronides until the plateau was achieved. The lowest possible concentration was selected
for cost-effectiveness of the assay. Optimal concentration of UDPGA was 2.5–5 mM for all
the other compounds except for methyltestosterone, which required 7.5 mM concentration
of co-substrate for maximal yield of MTG. The formation of the steroid glucuronides was
linearly proportional to the concentration of protein up to 0.5–1 mg/mL. The effect of
incubation time was tested up to 24 h and observed to reach the plateau after 6 h of
incubation at the latest. However, there was no evidence of breakdown of the glucuronide
conjugate during that time, which allowed an overnight incubation (12–15 h).













-NG 250 5 1 AG 500 2.5 1
-NG 500 5 0.75 d3-TG 500 5 1
-EPIMG 500 5 1 NG 500 5 1
-MTG 1000 2.5 0.5 -1-MEG 500 5 1
-MTG 1000 2.5 0.5 MTG 1000 7.5 0.5
-MEG 500-1000 2.5 0.75
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The larger scale enzymatic syntheses of the steroid glucuronides were carried out under
optimized conditions (Table 5) using 20 mL reaction volume. The excess of steroid
substrate was removed in LLE with dichloromethane. The more polar steroid glucuronide
remained in aqueous layer, but also some residue of starting material was found to remain
in that fraction. To increase purity of the product, a further purification was performed with
SPE. Retention of steroid substrate and glucuronide conjugate in SPE was examined as a
function of methanol concentration (1–100%). The polarities of these two compounds were
different enough for the complete isolation of the AAS glucuronide from steroid substrate
when methanol–water (60:40, v/v) was used in the final elution.
The synthesis method was suitable for producing steroid glucuronides in milligram amounts
(1.1–6.5 mg), with yields of 13–78% (Table 6). Steroid substrates with a 4-ene-3-one
structure and a sterically free 17 -OH position available for O-glucuronidation (NG and d3-
TG)  showed  superior  yields  of  77%  in  comparison  to  the  substrates  with  3-OH and
completely saturated or 1-ene A-ring structure (13–28%). Glucuronidation of
methyltestosterone was exceptional (14%), as the only possible site for O-glucuronidation
is the 17 -OH-group, though sterically hindered by the neighbouring 17 -CH3, which is
likely to inhibit the catalysis of the bulky UGT enzymes. Based on the detected formation
of MTG, although in low yield, it may be proposed that the structure still allows conjugation
to some extent in the absence of a more favorable functionality. Within the group of selected
compounds, 5 -androstane-3 ,17 -diol and its d5-labeled analogue were the only ones with
sterically non-hindered 3 - and 17 -hydroxyl groups, offering multiple sites for O-
glucuronidation.
Table 6. Synthesized steroid glucuronides and their yields.
Compound Yield (mg) Yield (%) Compound Yield (mg) Yield (%)
5-NG 1.3 16 AG 1.9 16
5-NG 1.1 13 d3-TG 6.5 77
5-EPIMG 1.4 25 NG 3.5 77
5-MTG 2.1 22 5-1-MEG 1.7 24




The structure of enzymatically synthesized steroid glucuronides was confirmed with MS
and NMR. MS gave molecular weight and specific fragmentation information, but NMR
was needed in order to confirm the position and configuration of glucuronidation. In positive
ion ESI MS spectra the abundant ammonium adduct ion [M+NH4]+ or protonated molecule
[M+H]+ were detected as base peaks and loss of glucuronide moiety was the main fragment
in MS/MS spectrum. In negative ion ESI MS spectra, the base peak for all AAS
glucuronides was the deprotonated molecule [M H]  that was fragmented to an intense
deprotonated glucuronic acid [Glu H]  as product ions in the MS/MS spectra. The positive
and negative ion MS and MS/MS spectra clearly indicate the presence of the glucuronide
moiety.  However,  the MS data does not provide unambiguous information on the site of
glucuronidation and for this reason NMR characterization was performed.
One-dimensional 1H NMR was used to determine the position of the glycosidic linkage and
the anomericity of the glucuronic acid moiety in the steroid glucuronides. Each glucuronide
spectrum contained the five methine signals arising from the glucuronic acid. The measured
vicinal 3JGH1,GH2 coupling constants of approximately 7.8 Hz are typical values between two
axial protons, and thus confirmed the -configuration for the glucuronic acid for each
glucuronide. Integration of the signals gave a 1:1 glucuronic acid/aglycone ratio indicating
the correct stoichiometry.
As the resulting steroid substrates (d4-5 -NG, 5 -MEG, d3-TG, NG, d3-NG, 5 1-MEG, and
MTG) contain only one possible site for glucuronidation, there was no ambiguity about the
position of the glycosidic linkage in the corresponding glucuronides. In the structures of AG
and 5 -EPIMG, there are two possible glucuronidation sites, namely hydroxyl groups in
positions 3 and 17. For these compounds 1H spectra of both steroid aglycone and
glucuronide were measured and compared. In 5 -androstane-3 ,17 -diol (A, steroid
aglycone)  H3  and  H17  resonate  downfield  to  the  steroid  bulk  region  and  can  be
distinguished from each other due to their different coupling patterns. H17 of steroid
aglycone  is  a  triplet  [219]  with  a  coupling  constant  of  8.5  Hz  while  H3  is  typically  a
multiplet resulting from several small couplings [220] Comparison of the steroid aglycone
spectrum with its glucuronide-conjugated product (AG) spectrum showed that the H17
signal shifted by 0.25 ppm downfield upon glucuronidation and also that H3 signal did not
shift, which suggests that the glucuronide, indeed, is a 17-O-glucuronide.
Comparison of aglycone and glucuronide 1H spectra also suggested that 5 -EPIMG is a 3-
glucuronide. This is because none of the methyl signals, including 17 -methyl, shifted upon
glucuronidation while H1, H2, and H3 shifted downfield by 0.09, 0.12, and 0.16 ppm,
respectively. NMR-characterization of 5 -NG, 5 -NG, 5 -MTG, and 5 -MTG has been
presented previously elsewhere [67].
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4.2 Sample preparation
Three different sample clean up procedures, namely LLE, SPE, and LPME were compared
previously [94] for AAS glucuronides in urine, concluding that the SPE and LPME methods
resulted in cleaner samples than LLE. LPME provided slightly better limits of detection and
specificity than SPE. However, the LPME method resulted in poor recoveries (8-19%) and
it  is  not  easily  automated,  and  therefore  SPE  was  chosen  for  future  development  of  the
sample clean up procedure. SPE of AAS glucuronides has previously [67,94,187,195] been
performed with C8 and C18 sorbents. Within this method development, as well as in earlier
research [94], the urine matrix clearly interfered with the ion traces of 5-MTG and 5-
MTG in authentic urine samples when extracted with C18 cartridge. Also, the recoveries
with the C18 column were insufficient. Therefore, various sorbent materials were
investigated, and in this application, the best selectivity was obtained with macroporous
polymeric sorbent cartridge containing both hydrophilic and lipophilic characters (Oasis
HBL 30 mg/1 cc). Methanol:water (1:9, v/v) and methanol:water (6:4, v/v) were optimized
as washing and elution steps, respectively.
4.3 Development of LCESI-MS/MS method for AAS glucuronides
Separation of AAS glucuronides and matrix components with HPLC was optimized.
Ionization in both positive and negative mode ESI was investigated, as well as the
fragmentation pattern in MS/MS measurements. Specific product ions and optimal collision
energies of each compound were determined. The developed method was validated and the
possibility to transfer it to other laboratories was investigated in inter-laboratory
comparison.
4.3.1 LC separation of AAS glucuronides
Separation of 5-MTG and 5-MTG with a C18 column was found to be insufficient in
earlier studies [94]. The HPLC separation was enhanced in order to achieve adequate
resolution between 5-MTG and 5-MTG, for which also the endogenous interference was
the most intense. Four different HPLC columns were tested during the development of the
HPLC method. One C18 column (Purospher STAR RP-18, endcapped, 55 mm x 2mm,
particle size 3 μm) and three cyano columns (Zorbax 300 SB-CN 150 mm x 2.1 mm (5 μm),
Discovery CN endcapped 1.0 x 150 mm (5 m) and Phenomenex Luna CN endcapped 2.0
x 150 mm (3 m)). In this application, the best specificity and selectivity was achieved with
endcapped Phenomenex Luna CN 2.0 x 150 mm (3 m) column. Cyano-substituted phase
material offers improved selectivity and the length of the column together with narrow
diameter and smaller particles provide better chromatographic performance. In a 25-minute
gradient run the steroids eluted in 14.1-20.6 min and resulted in fairly narrow and symmetric
peaks. The peak widths at half heights were 0.178-0.237 min, and peak symmetry factors
were 0.69-1.6 (Table 11). All the examined glucuronide-conjugated steroid metabolites
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were chromatographically separated, and the resolution of the most similar pair of
compounds (5-MTG and 5-MTG) was acceptable (Rs=1.0).
4.3.2 Ionization and MS detection of AAS glucuronides
Previous studies have shown ESI to be more sensitive than APCI or atmospheric pressure
photoionization (APPI) for steroid glucuronides and free anabolic steroids [187,189]. AAS
glucuronides can be detected in both polarities of ESI-MS detection, and the behavior of the
conjugates was investigated in both polarities.
The abundant ammonium adduct ion [M+NH4]+ was detected in positive ion ESI-MS for
the glucuronides with a saturated A-ring system, whereas for d3-TG, NG, and d3-NG with
4-ene-3-one structure, protonated molecule [M+H]+ was detected as a base peak. The ratio
of  protonated  molecule  and  ammonium adduct  ion  was  found to  strongly  depend on  the
proton  affinity  (PA)  of  the  compound,  where  a  higher  proton  affinity  resulted  in  the
formation of a stronger protonated molecule. Proton affinity of the 4-ene-3-one structure in
the steroid ring results in higher proton affinity than a hydroxyl group or carbonyl group
without a conjugated double bond [221]. For 5 -1-MEG and MTG, the relative abundance
of [M+NH4]+ and [M+H]+ was approximately equal. Formation of sodium adduct [M+Na]+
was also detected for most of the compounds, although with variable relative abundances.
In negative ion ESI, an intensive deprotonated molecule [M H]  was observed as the base
peak for all AAS glucuronides (Table 7). In negative ion ESI, the most potential site for
deprotonation is the carboxylic acid moiety of the glucuronic acid, as the steroid aglycones
are not ionized in negative ion ESI at all. These results are in good agreement with earlier
studies by Bowers and Sanaullah [105], Williams et al. [222], and Kuuranne et al. [187] and
[94], and gave evidence on the correct molecule weights of the synthesized steroid
glucuronides.
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Table 7. Positive and negative ion ESI-MS of AAS glucuronides.
POS ESI NEG ESI
Compound [M+H]+ [M+NH4]+ [M+Na]+ [M-H]-
5-NG n.d. 470 (100) n.d. 451 (100)
d4-5-NG n.d. 474 (100) n.d. 455 (100)
5-NG n.d. 470 (100) 475 (43) 451 (100)
5-EPIMG n.d. 498 (100) n.d. 479 (100)
5-MTG n.d. 500 (100) 505 (36) 481 (100)
5-MTG n.d. 500 (100) 505 (38) 481 (100)
5-MEG 479 (2) 496 (57) 501 (100) 477 (100)
AG n.d. 486 (100) 491 (6) 467 (100)
d5-AG n.d. 491 (100) 496 (10) 472 (100)
d3-TG 468 (100) 485 (41) 490 (66) 466 (100)
NG 451 (100) n.d. 473 (50) 449 (100)
d3-NG 454 (100) 471 (2) 476 (6) 452 (100)
5-1-MEG 479 (89) 496 (100) 501 (11) 477 (100)
MTG 479 (94) 496 (100) 501 (15) 477 (100)
The positive ion MS/MS spectra showed abundant product ions formed by loss of
glucuronide moiety without or with loss of one or two water molecules. The positive charge
stayed predominantly on the aglycone side, and only weak fragments were detected from
the glucuronic acid side, e.g. [Glu+H]+ = 177, [Glu+H H2O]+ = 159,
[Glu+H 2H2O]+ = 141 (Table 8). The negative ion MS/MS spectra of [M H]  showed
intense product ions derived from the deprotonated glucuronic acid [Glu H]  (Table 9). The
spectra also showed weak product ions formed by the cleavage of a glucuronic acid moiety
[M Glu] , followed by the abstraction of two hydrogens [M Glu 2H] , and losses



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The behavior of the AAS glucuronide conjugates is relatively uniform in both polarities of
ESI-MS detection. Negative ionization mode usually results in lower background, but the
negative ion mode fragmentation leads to formation of non-specific ions from the
glucuronide moiety, and therefore, LC–MS/MS method development was carried out in
positive ion mode. In positive ion mode MS, the base peak was most often the ammonium
adduct [M+NH4]+, indicating relatively low proton affinities (PA) of the compounds. The
protonated molecule [M+H]+ was the base peak for compounds containing conjugated
double bonds (d3-NG, NG, d3-TG, 5-1-MEG, and MTG). These results suggest that the
presence of the 4-ene-3-one structure in the aglycone moiety of steroid glucuronides favors
the formation of an abundant [M+H]+ ion and are in good correlation with earlier studies
[105,187,221,223].
The most abundant ion, ammonium adduct, or protonated molecule was selected as a
precursor  ion  for  following  MS/MS studies,  which  were  carried  out  for  determination  of
specific product ions and optimal collision energies of each compound. Some SRM ion
transitions were strongly interfered by the background ions at collision offset voltages of
20-25 V, which produced product ions formed by the losses of one or several water
molecules and cleavage of the glucuronide moiety, followed by the loss of water from the
steroid aglycone. Because urine is generally rich of endogenous steroid glucuronides and
glucuronide-conjugated compounds, which are fragmented similarly to the target
compounds, specificity problems were encountered. Therefore, the collision energy in the
MS/MS analysis was increased up to 45-70 V to produce specific product ions derived from
the dissociation of the aglycone moiety. The results showed significantly better specificity
than  those  produced  by  lower  collision  energy.  Precursor-product  ion  pairs  of  the  SRM
method with corresponding collision energies are listed in Table 10.
In  the  final  LCESI-MS/MS method, the detection was performed by following three
specific ions per analyte in SRM (Table 10). The collision energy was 15-70 V and due to
the technical characteristic of the instrument, analytical run was divided between three
segments. The first segment (0-15.80 min) included characteristic SRM ions for d3-NG, NG
and d3-TG with dwell time of 200 ms. The second segment (15.80-19.35 min) containing
ions for 5-1-MEG, MTG, d4-5-NG, 5-NG, 5-MTG, 5-MTG, d5-AG, and 5-MEG
were  monitored  with  dwell  time  of  90  ms.  5-EPIMG was the only analyte in the last
segment (19.35-25 min) with the dwell time of 450 ms.
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Table 10. Precursor-product ion pairs of AAS glucuronides in SRM method. CE = collision energy,
expressed as offset voltage, Tgt = Target, Q1 = qualifier1, Q2 = Qualifier 2. Dwell time (msec)
Compound Precursor ion (m/z) Product ion (m/z) CE Dwell time Segment
NG Tgt [M+H]+ = 451 m/z = 73 70 V 200 1
Q1 [M+H]+ = 451 m/z = 113 40 V 200 1
Q2 [M+H]+ = 451 [M+H-Glu]+ = 275 25 V 200 1
d3-NG Tgt [M+H]+ = 454 [M+H-Glu]+ = 278 25 V 200 1
Q1 [M+H]+ = 454 m/z = 73 70 V 200 1
Q2 [M+H]+ = 454 m/z = 113 40 V 200 1
d3-TG Tgt [M+H]+ = 468 m/z = 97 45 V 200 1
Q1 [M+H]+ = 468 [M+H-Glu]+ = 292 25 V 200 1
Q2 [M+H]+ = 468 [M+H-Glu-H2O]+ = 274 30 V 200 1
5-1-MEG Tgt [M+H]+ = 479 [M+H-Glu]+ = 303 20 V 90 2
Q1 [M+H]+ = 479 [M+H-Glu-H2O]+ = 285 20 V 90 2
Q2 [M+H]+ = 479 [M+H-Glu-2H2O]+ = 267 25 V 90 2
MTG Tgt [M+H]+ = 480 [M+H-Glu-H2O]+ = 286 30 V 90 2
Q1 [M+H]+ = 480 [M+H-Glu-2H2O]+ = 268 35 V 90 2
Q2 [M+H]+ = 480 [M+H-Glu]+ = 304 25 V 90 2
5-NG Tgt [M+NH4]+ = 470 [M+H-Glu- H2O]+ = 259 20 V 90 2
Q1 [M+NH4]+ = 470 [M+H-Glu-2H2O]+ = 241 30 V 90 2
Q2 [M+NH4]+ = 470 [M+H-Glu]+ = 277 15 V 90 2
d4-5G Tgt [M+NH4]+ = 474 [M+H-Glu]+ = 281 15 V 90 2
Q1 [M+NH4]+ = 474 [M+H-Glu-2H2O]+ = 245 30 V 90 2
Q2 [M+NH4]+ = 474 [M+H-Glu-H2O]+ = 263 20 V 90 2
5-MTG Tgt [M+NH4]+ = 500 [M+H-Glu-2H2O]+ = 271 20 V 90 2
Q1 [M+NH4]+ = 500 [M+H-Glu-H2O]+ = 289 20 V 90 2
Q2 [M+NH4]+ = 500 m/z = 161 50 V 90 2
5-MTG Tgt [M+NH4]+ = 500 [M+H-Glu-2H2O]+ = 271 20 V 90 2
Q1 [M+NH4]+ = 500 [M+H-Glu-H2O]+ = 289 20 V 90 2
Q2 [M+NH4]+ = 500 m/z = 161 50 V 90 2
d5-AG Tgt [M+NH4]+ =  491 [M+H-Glu-2H2O]+ = 262 30 V 90 2
Q1 [M+NH4]+ =  491 [M+H-Glu-H2O]+ = 280 15 V 90 2
Q2 [M+NH4]+ =  491 m/z = 92 70 V 90 2
5-MEG Tgt [M+NH4]+ =  496 [M+H-Glu-H2O]+ = 285 25 V 90 2
Q1 [M+NH4]+ =  496 m/z = 95 50 V 90 2
Q2 [M+NH4]+ =  496 [M+H-Glu-2H2O]+ = 267 30 V 90 2
5-EPIMG Tgt [M+NH4]+ = 498 m/z = 201 60 V 450 3
Q1 [M+NH4]+ = 498 [M+H-Glu-2H2O]+ = 269 30 V 450 3
Q2 [M+NH4]+ = 498 [M+H-Glu-H2O]+ = 286 20 V 450 3
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4.3.3 Validation
The recovery and repeatability of the analysis was determined with spiked urine samples
(200 ng/mL). Recovery of the SPE was good for all glucuronides (89-100%). Within-day
repeatability of the LC–ESI-MS/MS method was 2-10% (relative standard deviation (RSD))
and between-day repeatability was below 16% (RSD) for most of the compounds (except
for  d3-NG, NG and MTG), which could be considered as suitable for trace analysis of
compounds in a complex biological matrix. The repeatability of retention time was good
(0.1% within day and 0.8-1% between days). The relationship between peak areas and
concentrations of AAS glucuronides in urine is best described using a quadratic regression
model. The regression coefficient (R) of the quadratic curve for all the AAS glucuronides
was over 0.994 within the range of 1-60 ng/mL (Table  11).  For  most  of  the  AAS
glucuronides, the detection limits with one SRM-transition were from 1 to 10 ng/mL, but
40 ng/mL for 5-1-MEG and MTG, due to the complex nature of urine as matrix in analysis
of exogenous and endogenous AAS glucuronides.
Table 11. Recovery, repeatability, and detection limits of the method. Peak widths at half height, peak
symmetry factors and regression coefficients of quadratic fit for concentration versus peak area.







factor R**Within-day Between-day Injection
d3-NG 95 2.8 32 5.3 5 0.198 1.0 0.9968
NG 95 3.0 24 3.8 10 0.189 0.71 0.9942
d3-TG 95 3.3 16 3.4 5 0.187 0.96 0.9963
5-1-MEG 93 7.0 14 3.5 40 0.181 1.3 -
MTG 105 9.6 28 3.8 40 0.178 1.2 -
d4-5-NG 98 2.7 13 3.6 5 0.197 1.0 0.9949
5-NG 95 2.7 12 3.4 5 0.204 1.0 0.9955
5-MTG 98 2.3 13 3.3 10 0.205 0.69 0.9998
5-MTG 103 3.8 7.7 2.8 10 0.212 1.6 0.9966
d5-AG 100 4.2 13 4.2 1 0.192 1.2 0.9970
5-MEG 95 4.9 9.3 2.7 5 0.237 1.3 0.9996
5-EPIMG 89 2.1 16 3.4 1 0.207 1.1 0.9985
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The results obtained indicate that the developed LC–MS analysis provides a reliable method
for the detection of AAS glucuronides. However, the limits of detection measured with
standards prepared in pure solvent were one to two orders of magnitude lower than those
obtained with urine samples. This reveals that the selectivity of the method is limited due to
endogenous compounds in urine samples, despite the use of tandem mass spectrometry. The
number of compounds possessing identical or similar ion transitions in SRM and the limited
chromatographic resolution (due to a similar constitution of AAS glucuronides) is a
considerable problem with the analysis of AAS from urine.
4.3.4 Inter-laboratory comparison
Seven laboratories participated in the inter-laboratory comparison to evaluate the
performance and transferability of the method, as well as to assess the fitness-for-purpose.
Laboratories were requested to analyze individual and authentic urine samples resulting
from excretion studies with nandrolone, methenolone, and methyltestosterone. Samples
were provided at low (20 ng/ml) and high (200 ng/ml) concentration and the laboratories
performed the analysis of both levels as triplicates. Sample preparation was performed with
SPE as described in chapter 3.4. Six out of seven participating laboratories utilized triple
quadrupole mass spectrometers and one laboratory employed an ion trap analyzer. The
summary of instrumental parameters and metabolites identified in excretion study urine
samples is given in Table 12. Identification of prohibited compounds was based on the
WADA guidelines [218] and an independently used matrix for result evaluation by
calculation of identification (ID) points. A successful identification of one transition of an
analyte in the sample resulted in one ID-point, the maximum being 18 points per one steroid
glucuronide (three transitions per sample, samples at two concentration levels as triplicates).
Altogether 68% of urine samples containing 5-NG, 71% containing 5-MTG, and 95%
containing 5-MEG were successfully identified. In addition, two laboratories succeeded
in determining 5-MTG at low concentration levels in excretion sample. Two laboratories
experienced problems with respect to the chromatographic separation: one due to signals
interfering with the 5-NG; the other due to insufficient resolution of the methyltestosterone
metabolites (5-MTG  and  5-MTG).  The  results  obtained  with  the  ion  trap  mass
spectrometer and triple quadrupole mass spectrometers were similar when the precursor ion
was a protonated molecule, e.g. in the case of methenolone metabolite 5-MEG. However,
the limited stability of ammonium adducts with 5-NG, 5-MTG, and 5-MTG during the
isolation  of  the  precursor  ion  at  unit  resolution  resulted  in  poor  sensitivity  of  MS/MS
experiments in the ion trap mass spectrometer. Both ESI and APCI were equally employed
for the ionization of steroid glucuronide conjugates, and the main reasons for inconclusive
results were observed to relate to chromatographic issues. Based on the results in Table 12,
the developed method is transferable to other laboratories when triple quadrupole mass
spectrometers are used.
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Table 12. Interlaboratory test: Summary of instrumental parameters and detected compounds













































Argon Nitrogen Argon Argon Nitrogen Helium Nitrogen
Ion
transitions
2 3 3 3 3 2 3
Metabolite Identification points (max 18)
5-NG 13 18 18 0 18 0 18
5-MTG 0 0 18 18 0 0 0
5-MTG 0 18 18 18 18 0 18
5-MEG 12 18 18 18 18 18 18
4.4 Development of GCμAPPI-MS/MS method for AAS
Gas chromatography–mass spectrometry with electron ionization is still widely used in the
analysis of AAS. GC provides good chromatographic resolution, but the relative abundance
of the molecular ion may be low and the analytes are strongly fragmented in the electron
ionization process, which decreases the overall sensitivity. GC can also be connected to MS
with softer ionization techniques operating at atmospheric pressure. A heated nebulizer
(HN) microchip offers feasible interfacing of GC to API-MS. The HN microchip using
APCI (APCI) or APPI (APPI) provides high ionization efficiency and produces abundant
protonated molecules or molecular ions with minimal fragmentation. GC–APPI-MS/MS
method was developed for the determination of selected anabolic steroids in human urine.
The method was validated, and the proof of principle was tested with two authentic
excretion urine samples, and the results were compared with those obtained with
conventional GC–EI-MS.
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4.4.1 Combination of GC to API-MS with HN microchip using APPI
The positioning of the microchip and the krypton discharge lamp were the most critical
parameters, but the flow rates of the dopant and auxiliary gas also influenced the ionization
efficiency. All the parameters were optimized to achieve maximum sensitivity and stability.
The microchip nozzle was set at the right side of the orifice and the narrow sample jet was
directed about 1 mm left from the orifice to maximize stability and to minimize background
interference (Figure 6). The optimal position of the HN microchip nozzle was about 10-13
mm from the MS orifice for derivatized steroids but much shorter for underivatized steroids
(4.9 mm). Shorter distances generally decreased stability, whereas longer distances
decreased sensitivity but favored the formation of a radical cation. The vacuum UV lamp
was placed perpendicularly to the nozzle of the HN microchip and as close to the vaporized
sample jet as possible to achieve maximum ionization efficiency. Longer distance between
the UV lamp and the jet decreases the intensity of radiation due to absorption of photons by
air and resulting in decreased ionization efficiency.
Figure 6. Schematic (left) and picture (right) of the uAPPI setup and enlarged picture of HN chip (below).
Sensitivity  and  stability  were  optimal  with  dopant  and  nebulizer  gas  flow  rates  of  3.5
L/min and 80 mL/min, respectively. The heating power of the nebulizer chip was adjusted
to result in temperatures at approximately 300°C (underivatized) or 350 °C (derivatized) in
the chip to prevent adsorption and peak broadening. Toluene was chosen as dopant for
underivatized steroids, since it enables efficient proton transfer reaction for high proton
affinity steroids, and efficient ionization via charge exchange reaction for low proton
affinity steroids, which cannot be ionized by proton transfer. On the other hand,
chlorobenzene was the best dopant for derivatized steroids, as the ionization energies of




MS inlet HN chip
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4.4.2 Mass spectrometry
The underivatized AAS are most likely ionized via proton transfer reaction whereas charge-
exchange reactions become more favorable when AAS are trimethylsilylated. Positive ion
APPI spectra of the underivatized steroids with both carbonyl and hydroxyl groups (NAN,
NANm, DNZm, 17MDN, and MTS) showed an abundant [M+H]+ ion, whereas the steroids
possessing only hydroxyl functionality (MDNm and MTm) showed [M H]+ ions and
intense radical cations (M+•), as well as fragments formed by the loss of one or two water
molecules (Table 13). In compounds with a carbonyl group, the proton affinity (PA) is high
enough for the proton transfer, but for the compounds possessing only hydroxyl
functionality this route is not possible. Abundant [M H]+ ion was formed from MDNm and
MTm most likely via hydride abstraction but oxidation of a hydroxyl group to a carbonyl
group followed by proton transfer reaction is also possible.
Table 13. μAPPI mass spectra of underivatized anabolic androgenic steroids; m/z (rel.abund.).
[M+H]+ M [M-H]+ [M+H-H2O]+ [M-H2O]+ [M-H-H2O]+ [M+H-2 H2O]+ [M-2 H2O]+
NANm 277 (100) 259 (76)
MDNm 304 (47) 303 (97) 287 (45) 286 (100) 285 (98) 269 (79) 268 (34)




17MDN 301 (100) 283 (23)
The APPI–MS spectra of the TMS steroids with chlorobenzene as dopant show an abundant
radical cation (M+•), which was the base peak for all compounds except MDNm-TMS and
MTm-TMS (Figure 7). For MDNm-TMS the most abundant peak was [M H]+ at m/z 447,
while for MTm-TMS it was [M 15]+ at m/z 435. The APPI spectra of NANm-TMS and
MTm-TMS showed, in addition to the radical cation, a strong protonated molecule
([M+H]+) after subtraction of the theoretical relative abundance of the M+1 isotope peak of
the  M+• ion. With toluene and chlorobenzene as dopants, the APPI spectra were closely
similar except for the relative abundances of protonated molecules - the abundance of the
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protonated molecule being somewhat higher with toluene than with chlorobenzene. The
results show that TMS-derivatized AAS favor charge exchange reaction over proton
transfer, which is the predominant ionization reaction of underivatized AAS. Charge
exchange will take place if the ionization energy (IE) of the analyte is lower than that of the
reactant ion, which can be the radical cation of a dopant. The ionization energies of intact
TES, NAN, and MTS are reported to be 8.95, 8.85, and 9.02 eV, respectively [224]. Since
the ionization energies of intact AAS are about the same as those of toluene (8.8 eV) and
chlorobenzene (9.07 eV), intact AAS are not ionized efficiently via charge exchange but via
energetically more favorable proton transfer. Trimethylsilylation of the hydroxyl and
carbonyl groups of AAS results in less efficient proton transfer reactions than for intact AAS
because the proton affinities of the ether moieties of the TMS derivatives are lower than
those of the hydroxyl and carbonyl groups of the corresponding intact AAS. In addition to
this, the TMS group causes steric hindrance for the protonation of the ether oxygen. For
these reasons, charge exchange reactions become more favorable than proton transfer
reactions when AAS are derivatized with TMS, and ionization energies of the derivatized
AAS are well below the IE of chlorobenzene. An advantage of the TMS derivatives of AAS
being ionized via charge exchange reaction instead of proton transfer is that selectivity is
expected to improve when molecular ion M+. is formed. That is because in APPI, most of
the compounds (also interfering back-ground compounds) are ionized via proton transfer
reaction appearing at odd mass numbers, whereas molecular ions often appear at even mass
numbers. Sensitivity is also enhanced compared to EI, as the soft ionization in atmospheric
pressure results in more intensive molecular ion.
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The most abundant ion(s) were selected as precursor ion for the GC– APPI-MS/MS
analysis (Table 14). Orifice (declustering), focusing, and entrance potentials were optimized
to maximize the intensity of potential  precursor ions,  and they were fairly similar for all
compounds: namely 20, 200, and 10 V for the underivatized and 10–20, 175, and 4 V for
derivatized AAS, respectively. Loss of one or two water molecules was observed in all the
MS/MS spectra of the underivatized AAS with numerous structure-specific product ions.
The fragmentation patterns of the protonated molecules of DNZm and MTS, which have 4-
ene-3-one structure and angular methyl group (in C19) showed the same features: the
product ions at m/z 109 and m/z 97 were characteristic and the protonated molecule was
relatively stable. A detailed fragmentation mechanism for these ions has been presented
earlier by Williams et al. [222]. The protonated molecule of NAN, with 4-ene-3-one
structure  but  without  a  methyl  group at  C10,  was  also  relatively  stable,  and  the  MS/MS
spectra  showed  an  abundant  ion  at  m/z  109.  The  product  ion  spectrum  of  17MDN  was
exceptional as it did not show an abundant ion at either m/z 97 or m/z 109 even though it
contains both 4-ene-3-one structure and angular methyl group (C-19). The most abundant
fragments for 17MDN were m/z 121 and m/z 149, the structures of which have been
presented earlier [225] and [226]. The [M H]+ ion of the steroids containing 3 -hydroxyl
group (MDNm and MTm) instead of 4-ene-3-one structure was relatively unstable and the
product ions spectra showed abundant ions formed by loss of one or two water molecules.
In addition, numerous product ions were observed, originating from the dissociation of the
core ring structure.
In the MS/MS spectra of derivatized steroids, product ions formed by the loss of TMS
groups were the most abundant ions in the spectra of the TMS ether derivatives (MDNm,
NANm, and MTm) and structure-specific product ions formed by the fragmentation of the
steroid ring structure were the most abundant ions in the spectra of the TMS 3,5-dienol ether
derivatives  (TES,  NAN,  DNZm,  17MDN,  and  MTS)  (Table  14  and  Figure  8).  The
fragmentation characteristics of the TMS derivatives of AAS in EI have been discussed
earlier in more detail [202,227]. The fragmentation of the odd-electron molecular ions of
TMS derivatized steroids in MS/MS is similar to EI,  which could allow for theuse of EI
spectral libraries to support the identification of unknown TMS derivatized steroids [176].
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Table 14. Precursor (Q1) and product ions (Q3) with corresponding collision energies (CE) monitored in
GC– APPI-MS/MS after derivatization (TMS) or without derivatization (non-TMS).
TMS
AAS Q1 Q3 CE AAS Q1 Q3 CE
TES 432 M 209 30 MTS 446 M 301 30
432 M 196 30 (ISTD) 446 M 169 50
NAN 418 M 182 35 NANm 421 [M+H]+ 241 25
418 M 194 40 421 [M+H]+ 145 35
DNZm 456 M 208 45 MDNm 447 [M-H]+ 159 40
456 M 316 35 447 [M-H]+ 215 30
17MDN 444 M 206 30 MTm 435 [M-CH3]+ 255 30
444 M 339 30 435 [M-CH3]+ 173 40
non-TMS
AAS Q1 Q3 CE AAS Q1 Q3 CE
NANm 277 [M+H]+ 241 20 MTS 303 [M+H]+ 109 37
277 [M+H]+ 259 12 303 [M+H]+ 285 24
277 [M+H]+ 145 30 303 [M+H]+ 97 30
MDNm 303 [M-1]+ 201 25 DNZm 313 [M+H]+ 109 37
286 M -H2O 228 15 313 [M+H]+ 295 22
286 M -H2O 150 15 313 [M+H]+ 97 33
MTm 305 [M-1]+ 269 18 17MDN 301 [M+H]+ 121 30
306 M 230 15 301 [M+H]+ 283 17
306 M 270 15 301 [M+H]+ 149 23
NAN 275 [M+H]+ 109 37
275 [M+H]+ 257 24
275 [M+H]+ 239 25
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Figure 8. APPI-MS/MS spectra of the TMS derivatives of the studied anabolic androgenic steroids. CE = 35









4.4.3 Feasibility of GCμAPPI-MS/MS in analysis of AAS
The GC temperature program in both methods was optimized for fast separation. All the
analytes eluted between 4.3 and 6.0 min (derivatized) and 6.4-7.8 min (underivatized). In
general, the retention times were proportional to the polar moieties in the chemical structure
of the steroid and the size of the molecule. The steroids without a conjugated double bond
eluted first and then the steroids with 4-ene-3-one structure (III) The similar elution order
was observed with derivatized steroids (IV). TMS ether derivatives (MDNm, NANm, and
MTm)  eluted  first  and  then  the  TMS  3,5-dienol  ether  derivatives  (NAN,  17MDN,  TES,
MTS, and DNZm) (Fig. 2), indicating the later elution of compounds with 3,5-diene
structure. The peaks for derivatized steroids were narrow and it could be concluded that the
dead volumes of the interface were minimal and adsorption onto the vaporization channel
of the chip insignificant (Figure 9).
Figure 9. SRM chromatograms of a derivatized urine sample spiked with AAS at 1 ng/ml (MTm 2 ng/ml)
(solid line) and urine blank (dotted line).
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In doping analysis, qualitative determination is sufficient for exogenous anabolic steroids,
but quantification is required for steroid profiling of endogenous AAS. The feasibility of
GC–APPI–MS/MS in quantitative analysis of anabolic steroids in urine was therefore
validated with respect to LOD, LOQ, linearity, linear range, and repeatability. The
specificity of the method was good, since no interfering peaks were observed in the
chromatograms of the urine blank sample pooled from five individuals (Figure 9). The
method was repeatable and linear in the range between LOD-100 ng/mL (derivatized
compounds) and LOD-250 ng/ml (underivatized compounds), with correlation coefficients
(R2) above 0.996 for all compounds. The repeatability of injection and within-day
repeatability were similar and acceptable [228] in both methods (RSD under 10% for all
compounds). LODs determined with a signal-to-noise ratio criterion of three, using standard
deviation of the analyte peak height vs. background noise, were 0.2-1 ng/mL for
underivatized steroids and 0.05-0.5 ng/mL for derivatized steroids (Table 15). The
sensitivity is 2–10 times better with TMS-derivatized steroids than for underivatized
analytes, and the LOQs of 1 ng/mL were determined for derivatized anabolic steroids. The
difference is most likely because the TMS-derivatized steroids are more efficiently ionized
by charge exchange reaction than non-derivatized steroids by proton transfer reaction and
the background interference is lower with odd number radical cations. However, both
methods fulfil the current criteria of the minimum required performance levels of 2 or 5
ng/mL set by WADA [80].
Table 15. Repeatability of injection (n=6) for derivatized (TMS) at 10 ng/mL and non-derivatized (non-
TMS) at 25 ng/mL, LOD (ng/mL), peak symmetry factors (fs, at 5 ng/mL), and peak widths at half height Wh











25 ng/mL TMS non-TMS TMS non-TMS TMS non-TMS
MDNm 3.7 9.3 0.1 1.0 1.24 1.10 1.22 1.70
NANm 4.3 3.2 0.1 0.2 1.14 0.95 1.22 1.34
MTm 2.8 9.4 0.5 0.5 1.16 1.07 1.44 0.85
NAN 4.8 4.2 0.05 0.2 1.13 1.81 1.49 1.70
17MDN 5.4 2.5 0.1 0.3 0.94 1.36 1.43 1.63
DNZm 3.5 2.7 0.05 0.3 1.19 0.74 1.63 1.47
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Quantitative performance of the GCAPPI-MS/MS method was assessed by analyzing
two excretion urine samples and by comparing the results to those obtained by a
conventional GCEI-MS method. Three metabolites of methandienone (17MDN, MTm,
and MDNm) were identified and quantified from two authentic urine samples collected from
two voluntary male subjects after a single dose of methandione. Considering the qualitative
nature of routine analysis methods, the results obtained by both GCAPPI-MS/MS
methods and the conventional GCEI-MS method were in good agreement for all three
metabolites (Table 16).
Table 16. Concentrations of metabolites of methandienone in two authentic urine samples measured by
GCEI-MS and GC APPI-MS/MS after derivatization (TMS) or without derivatization (non-TMS).
Compound













17MDN 303 309 328 33 34 32
MDNm 388 331 579 86 105 151
MTm 373 309 461 171 161 212
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5 CONCLUSIONS
With respect to routine doping control analysis, LC–MS/MS offers a direct and sensitive
approach to the analysis of exogenous steroids as their glucuronides without a hydrolysis
process and time-consuming sample preparation that conventional GCMS methods
require. The ever-increasing number of prohibited substances with various physico-
chemical properties challenges laboratories to revise their analytical strategies to maintain
sensitive and cost-effective screening and confirmation methods. Implementation of LC–
MS-based methods with various instrument set-ups has become routine, thus allowing the
acquisition of data on glucuronide-conjugated prohibited compounds to support and
complement the traditional GCMS data. This might be especially advantageous in the
analysis of steroids with completely saturated structures that have low proton affinity and
for which the detection as aglycones is difficult with LCMS.
One significant drawback of the conjugate analysis is the lack of reference material. The in
vitro enzyme-assisted synthesis method offers a practical pathway for the rapid production
of stereochemically pure AAS glucuronides in milligram amounts that are sufficient for the
development of analytical methods. Due to a relatively simple reaction mixture and only
minor differences between the optimal conditions for the various AAS substrates, the
addition of a new structural analogue to the test set should be straightforward and thus also
easily applied.
The intact AAS glucuronides can be ionized in both positive and negative ion ESI. The most
representative mass spectrometric information on the AAS glucuronide structure was
obtained from MS/MS fragmentation studies in positive ion ESI, which is also the method
of choice for the routine LC–MS/MS analysis of AAS glucuronides. Glucuronide-
conjugated steroid metabolites were extracted by SPE and analyzed by LC–ESI-MS/MS
using positive ion mode and selected reaction monitoring. The developed method showed
robust sensitivity, quantitative performance, and repeatability, and the inter-laboratory
comparison demonstrated that it is transferable to other laboratories equipped with triple-
stage quadrupole mass spectrometers.
The resolving power of gas chromatography combined with efficient, but soft, ionization in
atmospheric pressure without fragmentation is an attractive combination. The heated
nebulizer microchip operated in APPI mode provides efficient ionization of anabolic
steroids  and  a  feasible  option  to  couple  GC  to  API-MS.  Two  sensitive  and  selective
GCμAPPI-MS/MS methods were developed, validated, and successfully applied to the
analysis of anabolic steroids in authentic urine samples. The anabolic steroids were analyzed
from urine samples without derivatization or as their TMS derivatives. Both methods
showed sensitivity and quantitative performance, demonstrating their potential for the
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analysis of biological samples. The TMS derivatives were ionized efficiently via charge
exchange reactions resulting in 2-10 times better sensitivity compared to non-derivatized
steroids, which were ionized mainly by proton transfer reaction. Furthermore, the
fragmentation of the molecular ions of the TMS derivatized steroids in μAPPI-MS/MS is
similar to EI, which facilitates the use of EI spectral libraries in the identification of TMS
derivatized steroids. The advantage of GC– APPI-MS/MS is soft and efficient ionization
that produces abundant molecular ions or protonated molecules with only slight
fragmentation, ensuring selectivity and sensitivity. Although the results were promising, the
usability of the heated nebulizer microchip requires further optimization. System assembly
is challenging and it is sensitive to small changes in positioning of the chip and lamp in
relation to the MS inlet. The open ion source design may result in repeatability problems as
the gases and particles from the surrounding air may enter the ionization region. Novel high
sensitivity capillary APPI (cAPPI) could resolve this problem. In cAPPI, the sample is
introduced, vaporized, and photoionized inside the extended heated capillary. The
surrounding air does not interfere in the ionization process and transmission into MS is
maximized resulting in excellent overall sensitivity [158].
Despite the extensive LCMS/MS method development described here, some compounds
were not suf ciently resolved from background interference. Enhanced sensitivity and
selectivity is required from the analytical methods due to the similarity of the AAS
metabolites and the multiplicity of endogenous compounds in the urine samples. Several
compounds can possess identical or similar ion transitions in SRM and the unit resolution
resolving  power  of  tandem  mass  spectrometry  is  not  always  sufficient.  Also,  given  the
similar chromatographic properties of AAS glucuronides, efficient chromatographic
separation is required. Enhanced chromatographic resolution, for example, with UPLC
and/or detection with high resolution mass spectrometry (HRMS) are promising techniques
for doping control analysis [114,137,211,229]. Furthermore, the full scan measurements in
HRMSs offer a retrospective option to re-process the raw data, which is a major advantage
in anti-doping, e.g. in case of new designer steroids. Untargeted profiling is an efficient tool
for doping analysis, as it provides the possibility of monitoring a large number of analytes
in  a  single  experiment  with  high  sensitivity  and  specificity.  The  evolution  of  mass
spectrometers has generated a multiplicity of techniques readily available for steroid
analytics. The choice of the most suitable analyzer together with the selection of matrix,
purification steps and separation methods enables efficient control of AAS misuse.
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